



Celsion Corporation
Investor Relations Department
997 Lenox Drive
Suite 100
Lawrenceville, NJ 08648
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: CLSN

| | |
|---------------|--|
| Last Trade: | 2.26 |
| Trade Time: | 9:51 AM ET Jun 27, 2017 |
| Change: | -0.11 ▼ (-4.549%) |
| Day Range | 2.22 - 2.39 |
| 52-Week Range | 2.03 - 19.61 |
| Volume | 92,095 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Celsion Corporation is an oncology drug development company focused on the development of efficient, effective, and targeted therapies for the treatment of cancer. Founded in 1985, the company has developed elegant therapeutic approaches that deliver high concentrations of widely used anti-cancer agents directly to the tumor site, maximizing efficacy while minimizing the side-effects of systemic treatments, with the goal of improving patient outcomes in underserved cancer indications. The foundation for this research is a heat-sensitive liposomal nanoparticle licensed from Duke Universit... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jun 22, 2017*
[Celsion Corporation Announces Cancellation of Registered Direct Offering](#)
- Jun 19, 2017*
[Celsion Corporation Announces \\$5.4 Million Registered Direct Offering](#)
- Jun 14, 2017*
[Celsion Corporation Regains Compliance with NASDAQ Listing Requirements](#)
- Jun 5, 2017*
[Celsion Announces Presentation of OVATION Study Findings at the ASCO 2017 Annual Meeting](#)
- May 26, 2017*
[Celsion Corporation Announces Stock Consolidation](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Mar 24, 2017*
[Annual Report \(10-K\)](#)
- Apr 4, 2017*
[Proxy Statement \(DEF 14A\)](#)
- May 12, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 10, 2016*
[Quarterly Report \(10-Q\)](#)
- Aug 15, 2016*
[Quarterly Report \(10-Q\)](#)